-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY), CytomX Therapeutics (CTMX) Begin Randomized Ph.2 Cohort Expansion in Ongoing Phase 1/2a Clinical Trial of Anti-CTLA-4 Probody Therapeutic BMS-986249
-
-
-
-
-
-
-
Form 4 CytomX Therapeutics, For: May 25 Filed by: Canaan IX L.P.
70,527 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

